IVUS Guidance for Extra Coronary Benefits
- IVUS group showed 48% lower MACE compared to angio-guided group (2.9% vs. 5.8%) at 1-year
- Higher percentage of post dilatation in IVUS group (76% vs. 54%, P < 0.001)
- Larger MLA post PCI in IVUS group
- MACE at 3-years was significantly lower in IVUS-guided group for both LM overall population (P = 0.04) and LM subgroups with distal lesions (P = 0.03)
- IVUS use was an independent predictor for fewer adverse events
- Further incremental benefit was shown in distal lesion subgroup receiving two stents
- Definite and Probable ST was significantly lower in the IVUS-guided group (P = 0.04)
- Results of a cost-effectiveness analysis in the United States demonstrated a reduction in MI, revascularization, and cardiac death among general CAD population treated with IVUS as compared to angiography alone.4
- IVUS was particularly effective in high risk subgroups, specifically in patients with diabetes, ACS, and Impaired Renal Function.5
- Evidence suggests that IVUS reduces the rate of severe cardiac events at 30 days, which may result in fewer MI related readmissions. Thirty-day readmissions are measured under the US CMS readmissions reduction program.6
- Over the lifetime of a CAD patient, IVUS could potentially save a total of $2,142 as compared to angiography alone.4
- The potential savings are even higher ($2,997, $2,879, and $3,257) when modeling patients with diabetes, ACS, and impaired renal function.4
- Cost per MI: $8,039†
- Cost per revascularization: $12,948**
Learn about the various options in Coronary Physiology, including FFR, DFR and Pd/Pa.
See the broadest portfolio of dependable, sophisticated PCI devices.
Get exclusive product updates, training and educational opportunities, and more.
Fill out a quick form and one of our sales representatives will be in touch.